Clinical Trial

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2022 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-08-06; most recent amendment 2022-08-28.
Status change: Not Yet Recruiting → Recruiting 2022-05-17
Trial Details
NCT Number NCT04996121
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 360 participants
Start Date 2021-12-06
Primary Completion 2025-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2022-08-30